CJC-1295 + Ipamorelin (5mg + 5mg)
Dual-receptor somatotropic research blend combining 5 mg CJC-1295 No DAC (GHRH-R) with 5 mg Ipamorelin (selective GHS-R1a) for investigating synergistic cAMP and PLC/Ca²⁺ growth hormone release kinetics.
Scientific Profile & Research Key Points: CJC-1295 + Ipamorelin
Dual-receptor somatotropic research blend combining 5 mg CJC-1295 No DAC (GHRH-R) with 5 mg Ipamorelin (selective GHS-R1a) for investigating synergistic cAMP and PLC/Ca²⁺ growth hormone release kinetics.
Active Batch Release Specifications (Lot SL-2026-118)
Analytical release verification for current CJC-1295 + Ipamorelin (5mg + 5mg) inventory
| Batch Lot # | Release Date | Analytical Method | Purity Spec | Endotoxin (LAL) | Moisture |
|---|---|---|---|---|---|
| SL-2026-118 | 2026-10-28 | Gradient RP-HPLC (Multi-Peak Resolution) + ESI-MS | ≥99.0% (Resolved Constituent Peaks) | <0.5 EU/mg | <2.8% (Karl Fischer) |
Laboratory Solubilization & Storage Protocol
Recommended Solvent / Handling
Sterile 0.9% Bacteriostatic Water (2.0 mL)
Temperature & Stability
Store lyophilized at -20°C; refrigerate reconstituted solution at 2°C–8°C for up to 28 days.
CJC-1295 + Ipamorelin — Technical Questions & Answers
How are the individual constituents of CJC-1295 + Ipamorelin verified in a single vial?
Because co-lyophilized blends contain multiple sequences with distinct retention times, Lot SL-2026-118 is evaluated via gradient RP-HPLC to resolve each constituent peak independently, paired with ESI-MS mass confirmation (3367.97 g/mol & 711.86 g/mol).
How do you calculate working stock aliquots for a multi-component blend like CJC-1295 + Ipamorelin?
Calculate each active constituent separately based on its labeled mass ratio (5mg + 5mg) divided by total diluent volume added. For example, adding 2.0 mL of sterile diluent yields proportional mg/mL concentrations for every component simultaneously.
What primary pathways are investigated using CJC-1295 + Ipamorelin?
Investigators study CJC-1295 + Ipamorelin in Dual Pituitary GHRH-R & GHS-R1a (Ghrelin Receptor) models. Primary published literature context: Raun K. et al., Eur J Endocrinol (1998) — Selective GHS-R1a agonism of Ipamorelin without ACTH/cortisol elevation (PMID: 9849822). All lots are supplied strictly for in-vitro laboratory experimentation.
Related Scientific Monographs
Peer-reviewed mechanism summaries and analytical protocols
CJC-1295, Ipamorelin, and Sermorelin: GHRH Analogues vs Ghrelin Receptor Agonists
A deep dive into somatotropic axis stimulation. Comparing GHRH receptor binding, DAC modification kinetics, ghrelin/GHS-R1a agonism, and pulsatile growth hormone secretion.
Gonadorelin, HCG, HMG and Kisspeptin: Mapping the Hypothalamic-Pituitary-Gonadal Axis
A comparative map of the HPG axis: GnRH receptor agonism (Gonadorelin), LH receptor mimetics (HCG), combined FSH/LH activity (HMG), and upstream GPR54 activation (Kisspeptin-10).
Human Growth Hormone (191aa): Somatropin Structure, Isoforms, and SEC-HPLC Analysis
A deep analysis of authentic 191-amino acid Somatropin vs 192-amino acid Somatrem. Size-exclusion chromatography (SEC), deamidation artifacts, and mass confirmation.